Forbion European Acquisition Corp.
FRBNW
NASDAQ Global Market0.74
USD
-0.08
- -
CIK
0001874495
CUSIP
G3619H110
Return %
Stock
S&P500
1Y
305.04
18.21
3Y
72.09
63.29
5Y
72.09
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 4001 Kennett Pike Wilmington DE United States of America 19807
- CIK
- 0001874495
- Similar Companies
- Business
- Forbion European Acquisition Corp. (FRBNW) operates as a blank check special purpose acquisition company with no significant ongoing operations, focusing on effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, primarily targeting late-stage opportunities in the European life sciences industry including biotechnology and human health sectors. Incorporated in 2021 and headquartered at 4001 Kennett Pike, Suite 302, Wilmington, Delaware, the company is sponsored by Forbion Growth Sponsor FEAC I B.V., an affiliate of Forbion, a life sciences venture fund manager based in Naarden, the Netherlands with additional offices in Munich, Germany, and Boston, Massachusetts. In its most significant development, Forbion European Acquisition Corp. completed a reverse merger with enGene, Inc. on October 31, 2023, resulting in its acquisition by enGene and the formation of enGene Holdings Inc., which trades on Nasdaq under the ticker ENGN; the transaction provided gross proceeds exceeding $138 million from trust cash, PIPE financing anchored by Forbion Growth and investors including BVF Partners, Omega Funds, Cowen Healthcare Investments, and others, to advance enGene's non-viral gene therapies for mucosal tissues such as detalimogene voraplasmid (EG-70) for non-muscle invasive bladder cancer. The entity now holds realised status within Forbion's Growth Fund portfolio, with FRBNW warrants associated with the prior structure continuing to trade post-combination.